Trial Profile
Phase I/II study of cediranib and olaparib in combination for treatment of recurrent platinum-sensitive papillary-serous ovarian, fallopian tube, or peritoneal cancer or for treatment of recurrent triple-negative breast cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 10 Apr 2024
Price :
$35
*
At a glance
- Drugs Cediranib (Primary) ; Olaparib (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Triple negative breast cancer
- Focus Adverse reactions; Therapeutic Use
- 08 Mar 2024 Planned End Date changed from 17 Jan 2025 to 13 Feb 2025.
- 08 Mar 2024 Planned End Date changed from 17 Jan 2025 to 13 Feb 2025.
- 02 Feb 2024 Planned End Date changed from 16 Oct 2024 to 17 Jan 2025.